The RPD designation is a positive catalyst for opaganib's regulatory pathway but does not change the company's acute cash crisis. Monitor for partnership or out-licensing discussions around the PRV, and for any financing events given the $4.1M cash position. The stock may see a short-term pop on the news, but fundamental distress remains the dominant factor.
Price Chart
Executive Summary
RedHill Biopharma announced that the FDA granted Rare Pediatric Disease (RPD) designation to opaganib for neuroblastoma, adding to its existing Orphan Drug designation. The RPD designation makes the company eligible for a Priority Review Voucher (PRV) upon approval, subject to conditions. This is a positive regulatory milestone for a preclinical-stage asset, but the company remains in severe financial distress with only $4.1M cash per the prior 20-F filing and a $5M market cap, meaning the PRV potential is highly speculative and contingent on successful clinical development and FDA approval.
Key Facts
- FDA granted Rare Pediatric Disease (RPD) designation to opaganib for neuroblastoma treatment.
- RPD designation provides eligibility for a Priority Review Voucher (PRV) subject to certain conditions.
- Opaganib already has Orphan Drug designation for neuroblastoma, offering potential 7-year marketing exclusivity if approved.
- Neuroblastoma market expected to be valued at approximately $3.5 billion in 2032.
- Preclinical data presented at AACR 2026 showed positive effects of opaganib as add-on therapy in neuroblastoma and TNBC models.
- Company had only $4.1M cash as of the 20-F filed April 27, 2026, with substantial doubt about going concern.
- Market cap is approximately $5M.
Financial Impact
PRV value historically ranges from $67M to $350M in sales, but opaganib is preclinical for neuroblastoma; no near-term revenue impact. The neuroblastoma market is estimated at $3.5B by 2032, but opaganib is years from potential commercialization.
Risk Factors
- Opaganib is preclinical for neuroblastoma; clinical failure risk is high.
- PRV eligibility is conditional and not guaranteed; voucher value is uncertain.
- Company has only $4.1M cash and substantial doubt about going concern per the 20-F.
- Nasdaq delisting risk remains active.
- No revenue from opaganib; Talicia commercialization is the only current revenue source.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003141 |
| Document: 0001178913-26-003141-index-headers.html | 0001178913-26-003141 |
| Document: 0001178913-26-003141-index.html | 0001178913-26-003141 |
| Document: 0001178913-26-003141.txt | 0001178913-26-003141 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers